Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
申请人:Wyeth Holdings Corporation
公开号:EP1950201A1
公开(公告)日:2008-07-30
This invention provides compounds of formula 1
wherein R1, G1, G2, R4, Z, X and n are defined herein, or a pharmaceutically acceptable salt thereof, which are useful as antineoplastic agents and in the treatment of polycystic kidney disease.
This invention provides compounds of formula I having the structure
wherein G1, G2, R1, R4, Z, n, and X are defined in the specification or a pharmaceutically acceptable salt thereof which are useful as antineoplastic agents and in the treatment of polycystic kidney disease.
Isomerisation about the C–N and CN bonds of E- and Z-amidines
作者:Anthony F. Hegarty、Anne Chandler
DOI:10.1039/c39800000130
日期:——
The unstable Z-formamidines are ‘frozen’ in the perpendicular configuration (6); ready isomerisation [via the conjugate acid (4)] occurs to the E-form (2).
Hexamethyldisilazane was reacted with formamides to generate N,N-disubstituent formimidamide, after which a reaction with sulfonamides was induced to form sulfonylformamidines. This protocol can be applied for arylformamidine formation in which anilines are used as substrates under optimized conditions. The advantages of this method are high efficiency, structural diversity in products with good yields